# A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects

> **NCT01577589** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 600 mg ceftaroline fosamil in 50 ml infusion volume
- **DRUG:** Placebo in 50 ml infusion volume
- **DRUG:** 600 ceftaroline fosamil in 250 ml infusion volume
- **DRUG:** Placebo in 250 ml infusion volume
- **DRUG:** 600 mg ceftaroline in 100 ml infusion volume
- **DRUG:** Placebo in 100 ml infusion volume

## Key facts

- **NCT ID:** NCT01577589
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2017-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01577589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01577589, "A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01577589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*